Twist Bioscience (TWST) Leerink Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Leerink Global Healthcare Conference 2026 summary
11 Mar, 2026Growth drivers and market positioning
Achieved 20% projected growth for FY2025 and 17% last quarter, outpacing sector peers through new product introductions, share gains, and account expansion.
Rapidly expanded total addressable market from $2B in 2020 to $7B in 2025 by launching new products and leveraging silicon chip economics.
Differentiation achieved via product quality, speed, cost, and customer support, with a focus on commercial excellence and e-commerce.
AI-driven drug discovery products have become a fast-growing segment, demonstrating agility in identifying and meeting emerging market needs.
Scale, automation, and software enable delivery of thousands of protein sequences in 15-20 days, supporting high-throughput drug discovery.
Financial performance and operational strategy
Maintained a 24% CAGR in revenue over three years, with gross margin expanding from low 30s to over 50%.
75%-80% of revenue growth drops to gross margin due to low variable costs; disciplined OpEx management supports adjusted EBITDA breakeven by Q4.
Shifted focus from milestone/royalty contracts to fee-for-service for faster revenue recognition, especially in monospecifics.
Bispecifics, enabled by Invenra B-Body technology, are expected to drive future royalties and growth.
Automated high-throughput facilities and targeted sales force expansion support scalable growth and margin improvement.
Market trends and customer engagement
AI and automation are transforming protein expression and drug discovery, with new startups and top pharma adopting these approaches.
Strategy is to offer a comprehensive menu (in vivo, in vitro, AI, various displays) to meet diverse customer needs and break revenue barriers.
Achieved $111M in therapeutics drug discovery revenue, doubling the $50M barrier and growing 21%-25% last year.
MRD segment is highly sticky due to speed, scale, and pricing advantages; MRD Express aims to reduce delivery from five days to one.
E-commerce rollout and territory-focused sales teams target under-penetrated academic and institutional markets.
Latest events from Twist Bioscience
- AI-driven workflows and new products fuel growth, margin gains, and market expansion.TWST
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - AI and MRD growth, automation, and innovation drive margin expansion and market leadership.TWST
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - B-Body® platform accelerates bispecific antibody discovery, driving growth and profitability.TWST
Corporate presentation17 Feb 2026 - All proposals passed, including director elections and auditor ratification, with no stockholder questions.TWST
AGM 20269 Feb 2026 - Q1 FY26 revenue up 17% to $103.7M, gross margin 52%, FY26 outlook raised, net loss narrowed.TWST
Q1 20262 Feb 2026 - Record Q3 revenue and margin gains, but net loss widened on a $44.9M impairment.TWST
Q3 20242 Feb 2026 - Express Genes and silicon-based innovation fuel growth, margin gains, and competitive edge.TWST
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Proprietary silicon chip drives rapid growth, innovation, and margin expansion across key markets.TWST
Jefferies Global Healthcare Conference1 Feb 2026 - Scalable DNA platform drives growth, margin expansion, and innovation across diverse markets.TWST
The 44th Annual William Blair Growth Stock Conference31 Jan 2026